Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Pharmaceutical Medicine
Published in:

14-07-2024 | Original Research Article

Measuring and Understanding Market Exclusivity Length for New Prescription Drugs in France, Australia, and the USA

Authors: Victor L. Van de Wiele, Aaron S. Kesselheim, Deborah Gleeson, Zhigang Lu, Sean S. Tu, Benjamin N. Rome

Published in: Pharmaceutical Medicine | Issue 4/2024

Login to get access

Abstract

Background

Originator drug manufacturers use several strategies to delay generic competition in the USA, but it remains unclear whether this results in longer market exclusivity compared to other countries.

Objectives

We sought to understand how drug market exclusivity lengths vary between the USA and two comparable countries.

Methods

We focused on drugs approved within 2 years of each other in the USA, France, and Australia from 1995 to 2005, and we compared the lengths of exclusivity from marketing approval through first generic competition or June 2023 using Kaplan–Meier analyses.

Results

Among 165 drugs in common between the USA and France, the median length of exclusivity was slightly longer in France (15.0 years, interquartile range [IQR]: 13.0–19.6) than the USA (14.5 years, IQR: 11.7–17.6). Among 100 drugs in common between the USA and Australia, the median length of exclusivity was longer in Australia (16.3 years, IQR: 13.9–22.4) than in the USA (14.4 years, IQR: 12.0–17.1).

Conclusions

Market exclusivity lengths in the USA are not longer than in France and Australia. Potential reasons include the larger US market and incentives that offer transient high generic drug prices in the USA for manufacturers that successfully challenge originator market exclusivity.
Literature
1.
2.
Rome BN, Lee CC, Kesselheim AS. Market exclusivity length for drugs with new generic or biosimilar competition, 2012–2018. Clin Pharmacol Ther. 2021;109:367–71.CrossRefPubMed
3.
Dave CV, Hartzema A, Kesselheim AS. Prices of generic drugs associated with numbers of manufacturers. N Engl J Med. 2017;377:2597–8.CrossRefPubMed
4.
Van de Wiele VL, Torrance AW, Kesselheim AS. Characteristics of key patents covering recent FDA-approved drugs. Health Aff (Millwood). 2022;41:1117–24.CrossRefPubMed
5.
Rome BN, Gagne JJ, Avorn J, Kesselheim AS. Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: a population-based cohort study. Am Heart J. 2021;233:109–21.CrossRefPubMed
6.
Mylan Laboratories Ltd. v. U.S. Food & Drug Administration. 910 F.Supp.2d. 299. December 2012.
7.
8.
Costa-Font J, McGuire A, Varol N. Price regulation and relative delays in generic drug adoption. J Health Econ. 2014;38:1–9.CrossRefPubMed
9.
10.
Son KB, Lopert R, Glesson D, et al. Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States. Global Health. 2018;14(1):1–11.
11.
Darrow JJ, Kesselheim AS. Drug development and FDA approval, 1938–2013. N Engl J Med. 2014;370(26): e39.CrossRefPubMed
12.
13.
14.
15.
16.
17.
18.
Mellish L, Karanges EA, Litchfield MJ, et al. The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers. BMC Res Notes. 2015;8:634.CrossRefPubMedPubMedCentral
19.
20.
Mistry R, Maheshwari D. Regulatory exclusivity strategies: further protection for pharmaceuticals in US, Europe and Canada. J Glob Trends Pharm Sci. 2015;6:2300–10.
21.
22.
Tsuji K, Tsutani K. Approval of new drugs 1999–2007: comparison of the US, the EU and Japan situations. J Clin Pharm Ther. 2010;35(3):289–301.CrossRefPubMed
23.
Kessler DA, Hass AE, Feiden KL, Lumpkin M, Temple R. Approval of new drugs in the United States: comparison with the United Kingdom, Germany, and Japan. JAMA. 1996;276(22):1826–31.CrossRefPubMed
24.
Downing NS, Zhang AD, Ross JS. Regulatory review of new therapeutic agents: FDA versus EMA, 2011–2015. N Engl J Med. 2017;376:1386–7.CrossRefPubMed
25.
Bloomfield D, Lu Z, Kesselheim AS. Improving the quality of US drug patents through international awareness. BMJ. 2022;377: e068172.CrossRefPubMed
26.
27.
Note, Crestor generics entered the market even later due to patent litigation, see Re Rosuvastatin Calcium Litigation (Fed. Cir. 2012).
28.
In Re Rosuvastatin Calcium Patent Litigation. 2012. 703 F.3d 511.
29.
Vokinger KN, Kesselheim AS, Avorn J, Sarpatwari A. Strategies that delay market entry of generic drugs. JAMA Intern Med. 2017;177(11):1665–9.CrossRefPubMed
30.
31.
Luo J, Seeger JD, Donneyong M, et al. Effect of generic competition on atorvastatin prescribing and patients’ out-of-pocket spending. JAMA Intern Med. 2016;176(9):1317–23.CrossRefPubMed
32.
Van de Wiele VL, Darrow JJ, Kesselheim AS. No parking here: a review of generic drug 180-day exclusivity and recent reform proposals. Yale J Health Policy Law Ethics. 2021;20:131.
33.
Grabowski H, Long G, Mortimer R. Recent trends in brand-name and generic drug competition. J Med Econ. 2014;17:207–14.CrossRefPubMed
34.
35.
36.
37.
38.
39.
40.
41.
Van de Wiele VL, Kesselheim AS, Sarpatwari A. Barriers to US biosimilar market growth: lessons from biosimilar patent litigation [published correction appears in Health Aff (Millwood). 2021 Oct; 40(10):1671]. Health Aff (Millwood). 2021;40(8):1198–205.PubMed
42.
Rome BN, Kesselheim AS. Biosimilar competition for Humira is here: signs of hope despite early hiccups. Arthritis Rheumatol. 2023;75(8):1325–7.CrossRefPubMed
43.
Metadata
Title
Measuring and Understanding Market Exclusivity Length for New Prescription Drugs in France, Australia, and the USA
Authors
Victor L. Van de Wiele
Aaron S. Kesselheim
Deborah Gleeson
Zhigang Lu
Sean S. Tu
Benjamin N. Rome
Publication date
14-07-2024
Publisher
Springer International Publishing
Published in
Pharmaceutical Medicine / Issue 4/2024
Print ISSN: 1178-2595
Electronic ISSN: 1179-1993
DOI
https://doi.org/10.1007/s40290-024-00527-w

Other articles of this Issue 4/2024

Pharmaceutical Medicine 4/2024 Go to the issue

Original Research Article

Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences

Leading Article

Increasing Diversity, Equity, Inclusion, and Accessibility in Rare Disease Clinical Trials

Original Research Article

Statistical Signal Detection Algorithm in Safety Data: A Proprietary Method Compared to Industry Standard Methods

Current Opinion

How Can General Managers Best Leverage Medical Affairs Now and in the Future?

Review Article

Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder